Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Krebs, I; Schmetterer, L; Boltz, A; Told, R; Vécsei-Marlovits, V; Egger, S; Schönherr, U; Haas, A; Ansari-Shahrezaei, S; Binder, S; MANTA Research Group.
A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
Br J Ophthalmol. 2013; 97(3):266-271
Doi: 10.1136/bjophthalmol-2012-302391
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Ansari Shahrezaei Siamak
- Haas Anton
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The current accepted standard treatment for neovascular age-related macular degeneration (AMD) consists of antivascular endothelial growth factor agents including ranibizumab and bevacizumab. The aim of the study was to examine whether bevacizumab is inferior to ranibizumab with respect to maintaining/improving visual acuity. In this prospective randomised parallel group multicentre trial patients aged more than 50 years with treatment naive nAMD were included at 10 Austrian centres. Patients were randomised to treatment either with 0.5 mg ranibizumab or 1.25 mg bevacizumab. Both groups received three initial monthly injections and thereafter monthly evaluation of visual acuity and the activity of the lesion. Re-treatment was scheduled as needed. Outcome measures were early treatment of diabetic retinopathy visual acuity, retinal thickness, lesion size and safety evaluation. A total of 321 patients were recruited of which four had to be excluded due to different reasons. Of the 317 remaining patients 154 were randomised into the bevacizumab group and 163 into the ranibizumab group. At month 12, there was a mean increase of early treatment of diabetic retinopathy visual acuity of 4.9 letters in the bevacizumab and 4.1 letters in the ranibizumab group (p=0.78). Furthermore, there were no significant differences in the decrease of retinal thickness, change of lesion size and number of adverse events between the groups. Bevacizumab was equivalent to ranibizumab for visual acuity at all time points over 1 year. There was no significant difference of decrease of retinal thickness or number of adverse events.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Angiogenesis Inhibitors - administration & dosage
- Antibodies, Monoclonal, Humanized - administration & dosage
- Bevacizumab -
- Dose-Response Relationship, Drug -
- Female -
- Follow-Up Studies -
- Humans -
- Intravitreal Injections -
- Macular Degeneration - drug therapy
- Macular Degeneration - pathology
- Macular Degeneration - physiopathology
- Male -
- Prospective Studies -
- Ranibizumab -
- Retinal Neovascularization - drug therapy
- Retinal Neovascularization - pathology
- Retinal Neovascularization - physiopathology
- Tomography, Optical Coherence -
- Treatment Outcome -
- Vascular Endothelial Growth Factor A - antagonists & inhibitors
- Visual Acuity -